65,437 trials
Chronic Spontaneous Urticaria
Primary: Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 — -13.6; -18.4; -13.5; -14.7 score on a scale — p=0.99
Hallux Valgus
Primary: AOFAS Score — 41.2; 77.0; 88.1 points
Diabetes Mellitus, Type 2
Primary: Glipizide Response as Measured by Area Over the Glucose Curve Between Time 0 and 240 Minutes According to Genotype — 4893.5; 5032.6; 6011 mg/dl x time(minutes)
Myopia
Primary: Distance Visual Acuity — -0.13; -0.12 logMAR
Tobacco Smoking
Primary: Intervention Feasibility: Participant Attendance — 5.32 Sessions
Pulmonary Arterial Hypertension
Primary: Change in Six-minute Walk Distance — 1.53; 9.45 meters
Pain · Quality of Life · Injection Site Reaction
Primary: Number of Participants With at Least One Severe (Grade 3) Solicited Local or Systemic Reactogenicity Event After Dose 1 of RZV (SHINGRIX®) in Each Study Group — 115…
COVID
Primary: Coagulopathy Associated With COVID-19 — -313; -129.5 ng/mL FEU
Moderate-to-severe Atopic Dermatitis
Primary: Investigator Global Assessment (IGA) (0-1) — 29.0; 5.9 percentage of participants
Pneumonia, Pneumococcal
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) — 7.4; 7.7; 7.5; 9.4 Percentage of Participants
Epilepsy
Primary: Qualitative Measure: Prioritization Cue-related Changes in the Neural Representation of Stimuli Reported as Binary for Prioritized and Unprioritized Item Decodability…
Sickle Cell Disease · Sickle Cell Anemia in Children · Sickle Cell Thalassemia
Primary: Sickle Cell Self-efficacy Scale Reported by Adolescents — 34.6 units on a scale
Healthy
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 1; 2; 3; 3 Participants
Advanced Breast Cancer
Primary: Overall Response Rate (ORR) — 1 Participants
Healthy
Primary: Early Liver Stage: Number of Participants Over Time With Positive Parasitemia — 6; 3; 2; 1 Participants